SlideShare a Scribd company logo
1 of 49
Chapter 24 
Drugs Treating Mild to Moderate 
Pain, Fever, Inflammation, and 
Migraine Headache 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Fever 
• Temperature regulation is a function of the 
hypothalamus. 
• Normally, a homeostatic balance exists between body 
heat generated and body heat lost. 
• Fever is the result of fever-inducing substances called 
pyrogens. 
• Fever causes activation of monocytes/macrophages, 
which in turn secrete cytokines. 
• Cytokines increase the synthesis and secretion of 
prostaglandin in the hypothalamus. 
• This causes the hypothalamus to reset the body 
temperature. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Inflammation 
• Numerous types of stimuli cause the inflammatory 
response. 
• The classic signs of local inflammation are swelling, heat, 
redness, pain, and loss of function. 
• Acute inflammation is divided into vascular and cellular 
responses. 
• The vascular response occurs almost immediately after 
the injury. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Inflammation (cont.) 
• The cellular response is divided into four phases: 
– Margination of white blood cells (WBCs) to the 
periphery of the blood vessels 
– Emigration of WBCs—the WBCs migrate into the 
tissue spaces. 
– Chemotaxis—cellular debris become more 
“attractive” to the WBCs. 
– Phagocytosis—neutrophils and monocytes engulf 
cellular debris. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prostaglandin Synthesis 
• Prostaglandins modulate some components of 
inflammation, body temperature, pain transmission, platelet 
aggregation, and many other body actions. 
• They are derived from arachidonic acid, which is liberated 
from the cell membrane in response to physical, chemical, 
hormonal, bacterial, or other stimuli. 
• They are converted from arachidonic acid to prostaglandins 
by the enzyme cyclooxygenase (COX). 
• There are two forms of the COX enzyme: COX-1 and COX- 
2. 
• COX-1 synthesizes prostaglandins that are involved in the 
regulation of normal cell activity. 
• COX-2 appears to produce prostaglandins mainly at the 
sites of inflammation. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prostaglandin Synthesis (cont.) 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Pain 
• The physiologic mechanisms involved in the pain 
response are complex. 
• The sensation of peripheral pain begins in afferent 
neurons called nociceptors. 
• These receptors are activated by chemical mediators, 
such as prostaglandins, histamine, bradykinin, and 
serotonin.
Platelet Aggregation 
• Simply speaking, platelet aggregation is the clumping 
together of platelets in the blood. 
• Platelet aggregation can be a beneficial process. 
• Platelet aggregation can also be harmful. It is the first 
step in a sequence of events that leads to the formation 
of a thrombus. 
• The risk of platelet aggregation is increased in patients 
who smoke and have hypercholesterolemia. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Migraine Headache 
• The two major types of migraine headache: 
– Migraine with aura 
– Migraine without aura 
• It is postulated that migraine begins when intracranial 
blood vessels dilate. 
• This dilation stimulates the trigeminovascular system, 
resulting in abnormally excitable neurons that send pain 
impulses to the brain’s pain receptors. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Drugs to Treat Inflammation and Fever 
• Salicylates, NSAIDs, and para-aminophenol derivative 
drugs are used to treat inflammation and fever in a 
variety of conditions. 
• Salicylates are used in managing conditions ranging from 
a simple headache to acute myocardial infarction (MI). 
• NSAIDs are used primarily as anti-inflammatory drugs 
but are also used extensively as analgesics. 
• Prototype drug: acetylsalicylic acid (aspirin) 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Aspirin: Core Drug Knowledge 
• Pharmacotherapeutics 
– Treat mild-to-moderate pain, prevent platelet 
aggregation 
• Pharmacokinetics 
– Absorbed in the stomach and small intestines; highly 
protein bound 
• Pharmacodynamics 
– Fever: inhibited PGE2 synthesis in the hypothalamus 
– Inflammation: peripheral inhibition of prostaglandin 
– Antiplatelet: irreversible inhibition of thromboxane 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
A2
Aspirin: Core Drug Knowledge (cont.) 
• Contraindications and precautions 
– Hypersensitivity, peptic ulcer disease, or bleeding 
disorders, and children with illness 
• Adverse effects 
– Renal failure, abnormal bleeding, GI upset, 
drowsiness, and confusion 
• Drug interactions 
– Other drugs that are highly protein bound 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Aspirin: Core Patient Variables 
• Health status 
– Assess for contraindications to therapy. 
• Life span and gender 
– Contraindicated in the last trimester of pregnancy 
• Lifestyle, diet, and habits 
– Assess use of OTC medications. 
• Environment 
– Assess understanding of drug therapy. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Aspirin: Nursing Diagnoses and Outcomes 
• Acute or chronic pain related to ineffectiveness of aspirin 
– Desired outcome: The patient will contact the 
prescriber if pain persists. 
• Risk for Injury: GI bleeding, hepatic or renal toxicity 
related to aspirin therapy 
– Desired outcome: The patient will avoid injury by 
contacting the prescriber if any signs of toxicity 
occur. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Aspirin: Nursing Diagnoses and Outcomes 
(cont.) 
• Disturbed Sensory Perception (visual and auditory) 
related to blurred vision or tinnitus 
– Desired outcome: The patient will contact the 
prescriber if blurred vision or tinnitus occurs. 
• Ineffective Protection related to blood dyscrasias or rash 
– Desired outcome: The patient will contact the 
prescriber if any signs of blood dyscrasias or rash 
occur. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Aspirin: Nursing Diagnoses and Outcomes 
(cont.) 
• Deficient Fluid Volume related to nausea and vomiting 
– Desired outcome: The patient will avoid 
dehydration by contacting the prescriber if persistent 
nausea or vomiting occurs. 
• Risk for Injury related to self-medication 
– Desired outcome: The patient will avoid injury by 
taking aspirin as prescribed. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Aspirin: Planning and Interventions 
• Maximizing therapeutic effects 
– Give with milk or food to decrease GI upset. 
– When giving aspirin for its cardiovascular properties, 
use uncoated aspirin. 
• Minimizing adverse effects 
– Do not administer aspirin to a patient with a medical 
condition that contraindicates its use. 
– It is important to monitor closely patients with pre-existing 
medical conditions or those on drug therapy 
that may interact with aspirin. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Aspirin: Teaching, Assessment, and 
Evaluations 
• Patient and family education 
– Teach proper administration of medication. 
– Discuss side effects of therapy. 
• Ongoing assessment and evaluation 
– Monitor the patient who is taking aspirin for signs 
and symptoms of GI distress or bleeding, anemia, 
hepatotoxicity, and renal failure. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Question 
• Why is aspirin contraindicated in children with varicella? 
– A. Can cause bleeding from skin lesions 
– B. Will decrease effectiveness of antibiotic therapy 
– C. Can cause increased fever 
– D. Can cause Reye syndrome
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Answer 
• D. Can cause Reye syndrome 
• Rationale: Aspirin is contraindicated in children with 
varicella or flu-like illness because it is associated with 
the occurrence of Reye syndrome.
Nonsteroidal Anti-Inflammatory Drugs 
• The NSAIDs are grouped by chemical classes. 
• NSAIDs all inhibit COX and prostaglandin synthesis. 
• The therapeutic efficacy of an NSAID in a particular 
patient is based on clinical response and usually cannot 
be predicted before its use. 
• All NSAIDs carry a Black Box warning stating that they 
increase the risk of MI and stroke. 
• Prototype drug: ibuprofen 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ibuprofen: Core Drug Knowledge 
• Pharmacotherapeutics 
– Arthritis, mild-to-moderate pain, primary 
dysmenorrhea, migraine headache, and fever 
• Pharmacokinetics 
– Absorbed from the GI system. Peak: 1 to 2 hours. 
Highly protein bound and is metabolized in the liver 
• Pharmacodynamics 
– Inhibited synthesis or release of prostaglandins 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ibuprofen: Core Drug Knowledge (cont.) 
• Contraindications and precautions 
– GI disease 
• Adverse effects 
– GI upset and bleeding, hepatotoxicity, and acute 
renal failure. Increases risk of CVA or MI with 
prolonged use. 
• Drug interactions 
– Similar to those of salicylates 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ibuprofen: Core Patient Variables 
• Health status 
– Assess for contraindications to therapy. 
• Life span and gender 
– Assess age before administration of drug. 
• Lifestyle, diet, and habits 
– Assess other OTC use. 
• Environment 
– Assess environment where drug will be given. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ibuprofen: Nursing Diagnoses and 
Outcomes 
• Acute or Chronic Pain related to ineffectiveness of 
ibuprofen 
– Desired outcome: The patient will contact the 
prescriber if pain persists. 
• Increased Risk for Injury related to incorrect self-administration 
or to drug-induced GI bleeding or hepatic 
and renal toxicity 
– Desired outcome: The patient will remain free of 
injury by taking the drug only as directed. In 
addition, the patient will be able to explain the 
importance of contacting the health care provider 
immediately if any adverse effects occur. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ibuprofen: Nursing Diagnoses and 
Outcomes (cont.) 
• Increased Risk for Deficient Fluid Volume related to 
nausea and vomiting 
– Desired outcome: The patient will contact the 
prescriber immediately if intractable nausea or 
vomiting occurs. 
• Disturbed Sensory Perception (visual) related to blurred 
vision 
– Desired outcome: The patient will discontinue 
ibuprofen immediately and contact the health care 
provider if vision is affected. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ibuprofen: Nursing Diagnoses and 
Outcomes (cont.) 
• Ineffective Protection related to blood dyscrasias 
– Desired outcome: The patient will contact the 
prescriber immediately if any signs and symptoms of 
blood dyscrasias occur. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ibuprofen: Planning and Interventions 
• Maximizing therapeutic effects 
– Give ibuprofen with milk or food to decrease gastric 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
distress. 
• Minimizing adverse effects 
– Closely monitor patients with pre-existing medical 
conditions or drug therapy that may interact with 
ibuprofen.
Ibuprofen: Teaching, Assessment, and 
Evaluations 
• Patient and family education 
– Teach patient about cardiovascular risk from 
medication. 
– Teach about side effects of drug therapy. 
• Ongoing assessment and evaluation 
– Monitor for side effects of therapy. 
– Therapy is considered effective if the patient is free 
of fever, pain, or inflammation and is free from 
adverse effects. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Question 
• Why were all NSAIDs given a Black Box warning by the 
FDA? 
– A. Risk of MI and CVA is increased with use of 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
NSAIDs. 
– B. Risk of GI bleeding is increased with use of 
NSAIDs. 
– C. NSAIDs can cause kidney failure. 
– D. NSAIDs can cause hepatic failure.
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Answer 
• A. Risk of MI and CVA is increased with use of 
NSAIDs. 
• Rationale: All NSAIDs have a risk of causing MI or 
CVA; the risk increases with prolonged use of the 
medication.
Para-Aminophenol Derivatives 
• Para-aminophenol derivative is an analgesic and 
antipyretic available in the United States. 
• Prototype drug: acetaminophen (Tylenol) 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Acetaminophen: Core Drug Knowledge 
• Pharmacotherapeutics 
– Used to treat fever or mild pain 
• Pharmacokinetics 
– Administered orally. Absorbed: GI tract. Peak: 60 
minutes. T1/2: 1 to 3.5 hours 
• Pharmacodynamics 
– Primarily centrally acting; inhibits prostaglandin 
synthesis in the CNS 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Acetaminophen: Core Drug Knowledge 
(cont.) 
• Contraindications and precautions 
– Hepatic disease, viral hepatitis, or alcoholism 
• Adverse effects 
– Generally well tolerated; overdose of medication can 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
be fatal 
• Drug interactions 
– Activated charcoal, antacids, ethanol, hydantoins, 
warfarin, and sulfinpyrazone
Acetaminophen: Core Patient Variables 
• Health status 
– Assess pain level and current medical conditions. 
• Life span and gender 
– Pregnancy category B 
• Lifestyle, diet, and habits 
– Ask about other OTC medication use. 
• Environment 
– Determine patient’s understanding of drug use. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Acetaminophen: Nursing Diagnoses and 
Outcomes 
• Acute or Chronic Pain related to ineffectiveness of 
acetaminophen 
– Desired outcome: The patient will contact the health 
care provider if pain persists. 
• Risk for Injury related to drug-induced hepatic and renal 
toxicity or to improper self-medication 
– Desired outcome: The patient will take drug as 
directed and contact the health care provider if any 
signs of toxicity occur. 
• Ineffective Protection related to potential blood dyscrasias 
– Desired outcome: The patient will contact the health 
care provider if any signs of blood dyscrasias occur. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Acetaminophen: Planning and 
Interventions 
• Maximizing therapeutic effects 
– Acetaminophen can be administered without regard 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
to meals. 
• Minimizing adverse effects 
– Assess patients for medical conditions that contradict 
the use of acetaminophen. 
– Coordinate periodic CBC, platelet count, and liver and 
renal function tests for patients on long-term 
therapy.
Acetaminophen: Teaching, Assessment, 
and Evaluations 
• Patient and family education 
– Teach patient to take medication as prescribed. 
– Teach side effects of medication. 
– Instruct that many OTC medications contain Tylenol. 
• Ongoing assessment and evaluation 
– Monitor patient for side effects from the medication. 
– Therapy is considered effective if patient is free of 
fever and pain. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Question 
• Which of the following patients is Tylenol contraindicated 
in? 
– A. 25 year old with headache 
– B. 45 year old with GI bleeding 
– C. 52 year old with hepatitis C 
– D. 62 year old with osteoarthritis
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Answer 
• C. 52 year old with hepatitis C 
• Rationale: Tylenol is contraindicated in patients with 
impaired liver/hepatic function.
Serotonin-Selective Drugs 
• Serotonin-selective drugs are used to relieve pain and 
inflammation related to migraine headache. 
• They are not useful for other types of headache or 
inflammation that occur elsewhere in the body. 
• These drugs are also known as “triptans” because the 
generic name of these drugs ends as such. 
• The triptans are considered first-line drugs for the 
treatment of acute migraine headache. 
• Prototype drug: sumatriptan (Imitrex) 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Sumatriptan: Core Drug Knowledge 
• Pharmacotherapeutics 
– Acute migraine headache and cluster headache 
• Pharmacokinetics 
– Administered orally, intranasally, or subcutaneously. 
Metabolized in the liver and excreted by the kidneys. 
• Pharmacodynamics 
– Selective for 5-HT1B/1D receptors located on cranial 
blood vessels and sensory nerves of the 
trigeminovascular system. 
– Stimulation of these receptors results in 
vasoconstriction. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Sumatriptan: Core Drug Knowledge 
(cont.) 
• Contraindications and precautions 
– Coronary artery disease and ischemic cardiac 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
diseases 
• Adverse effects 
– Coronary artery vasospasm, cardiac dysrhythmias 
angina, myocardial ischemia, and dizziness 
• Drug interactions 
– Selective serotonin reuptake inhibitors and 
monoamine oxidase inhibitors
Sumatriptan: Core Patient Variables 
• Health status 
– Assess the characteristics of the headache. 
• Life span and gender 
– Pregnancy category C 
• Lifestyle, diet, and habits 
– Identify trigger factors for headaches. 
• Environment 
– Given in the outpatient setting 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Sumatriptan: Nursing Diagnoses and 
Outcomes 
• Risk for Tissue Perfusion, Impaired, related to 
cardiovascular or cerebrovascular events 
– Desired Outcome: The patient will recognize the 
signs and symptoms of cardiovascular or 
cerebrovascular events and seek medical assistance 
immediately. 
• Risk for Injury related to weakness, dizziness or syncope, 
or lightheadedness 
– Desired Outcome: The patient will remain free of 
injury while taking sumatriptan. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Sumatriptan: Planning and Interventions 
• Maximizing therapeutic effects 
– Confirm diagnosis of type of headache the patient is 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
having. 
– Administer drug as soon as headache begins. 
• Minimizing adverse effects 
– Assess the patient for a history of cardiovascular or 
cerebrovascular disorder. 
– After administering sumatriptan, monitor for signs 
and symptoms of vasospasm and allergy.
Sumatriptan: Teaching, Assessment, and 
Evaluations 
• Patient and family education 
– Teach how to take medication properly. 
– Teach side effects of medication. 
– Teach patient to identify triggers. 
• Ongoing assessment and evaluation 
– Evaluate patients taking sumatriptan for the 
cessation of headache and for signs and symptoms of 
vasospastic events. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Question 
• Which of the following is the most serious adverse effect 
of sumatriptan? 
– A. Cardiac event 
– B. Respiratory event 
– C. Urinary event 
– D. GI event
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Answer 
• A. Cardiac event 
• Rationale: The most serious adverse effect is cardiac 
events, however, they rarely occur.

More Related Content

What's hot

Ppt chapter 18
Ppt chapter 18Ppt chapter 18
Ppt chapter 18stanbridge
 
Ppt chapter 45
Ppt chapter 45Ppt chapter 45
Ppt chapter 45stanbridge
 
Ppt chapter 22
Ppt chapter 22Ppt chapter 22
Ppt chapter 22stanbridge
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20stanbridge
 
Ppt chapter 51
Ppt chapter 51Ppt chapter 51
Ppt chapter 51stanbridge
 
Ppt chapter 31
Ppt chapter 31Ppt chapter 31
Ppt chapter 31stanbridge
 
Ppt chapter 14
Ppt chapter 14Ppt chapter 14
Ppt chapter 14stanbridge
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37stanbridge
 
Ppt chapter 50
Ppt chapter 50Ppt chapter 50
Ppt chapter 50stanbridge
 
Ppt chapter 19
Ppt chapter 19Ppt chapter 19
Ppt chapter 19stanbridge
 
Ppt chapter 26
Ppt chapter 26Ppt chapter 26
Ppt chapter 26stanbridge
 
Ppt chapter 15
Ppt chapter 15Ppt chapter 15
Ppt chapter 15stanbridge
 
Ppt chapter 11-1
Ppt chapter 11-1Ppt chapter 11-1
Ppt chapter 11-1stanbridge
 
Ppt chapter 21
Ppt chapter 21Ppt chapter 21
Ppt chapter 21stanbridge
 
Ppt chapter 23
Ppt chapter 23Ppt chapter 23
Ppt chapter 23stanbridge
 
Ppt chapter 08-1
Ppt chapter 08-1Ppt chapter 08-1
Ppt chapter 08-1stanbridge
 
Ppt chapter 23-1
Ppt chapter 23-1Ppt chapter 23-1
Ppt chapter 23-1stanbridge
 
Ppt chapter 41
Ppt chapter 41Ppt chapter 41
Ppt chapter 41stanbridge
 
Ppt chapter 20-1
Ppt chapter 20-1Ppt chapter 20-1
Ppt chapter 20-1stanbridge
 

What's hot (19)

Ppt chapter 18
Ppt chapter 18Ppt chapter 18
Ppt chapter 18
 
Ppt chapter 45
Ppt chapter 45Ppt chapter 45
Ppt chapter 45
 
Ppt chapter 22
Ppt chapter 22Ppt chapter 22
Ppt chapter 22
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20
 
Ppt chapter 51
Ppt chapter 51Ppt chapter 51
Ppt chapter 51
 
Ppt chapter 31
Ppt chapter 31Ppt chapter 31
Ppt chapter 31
 
Ppt chapter 14
Ppt chapter 14Ppt chapter 14
Ppt chapter 14
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37
 
Ppt chapter 50
Ppt chapter 50Ppt chapter 50
Ppt chapter 50
 
Ppt chapter 19
Ppt chapter 19Ppt chapter 19
Ppt chapter 19
 
Ppt chapter 26
Ppt chapter 26Ppt chapter 26
Ppt chapter 26
 
Ppt chapter 15
Ppt chapter 15Ppt chapter 15
Ppt chapter 15
 
Ppt chapter 11-1
Ppt chapter 11-1Ppt chapter 11-1
Ppt chapter 11-1
 
Ppt chapter 21
Ppt chapter 21Ppt chapter 21
Ppt chapter 21
 
Ppt chapter 23
Ppt chapter 23Ppt chapter 23
Ppt chapter 23
 
Ppt chapter 08-1
Ppt chapter 08-1Ppt chapter 08-1
Ppt chapter 08-1
 
Ppt chapter 23-1
Ppt chapter 23-1Ppt chapter 23-1
Ppt chapter 23-1
 
Ppt chapter 41
Ppt chapter 41Ppt chapter 41
Ppt chapter 41
 
Ppt chapter 20-1
Ppt chapter 20-1Ppt chapter 20-1
Ppt chapter 20-1
 

Viewers also liked

Ppt chapter 07-1
Ppt chapter 07-1Ppt chapter 07-1
Ppt chapter 07-1stanbridge
 
INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil
INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil
INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil BioRincon.es
 
Cns drugs outline
Cns drugs  outlineCns drugs  outline
Cns drugs outlineraj kumar
 
Greece
GreeceGreece
Greece368243
 
cases and treatment of peptic ulcers
cases and treatment of peptic ulcerscases and treatment of peptic ulcers
cases and treatment of peptic ulcersMjnoOntk Ana
 
Ppt chapter 52-1
Ppt chapter 52-1Ppt chapter 52-1
Ppt chapter 52-1stanbridge
 
Anti inflammatory drugs
Anti inflammatory drugsAnti inflammatory drugs
Anti inflammatory drugsAbubakar Fago
 
02.06.12(a): Drugs and the Liver
02.06.12(a): Drugs and the Liver02.06.12(a): Drugs and the Liver
02.06.12(a): Drugs and the LiverOpen.Michigan
 
Some Spotlights about Pain management
Some Spotlights about Pain managementSome Spotlights about Pain management
Some Spotlights about Pain managementAhmed El-Sawy
 
Central nervous system drugs /certified fixed orthodontic courses by Indian d...
Central nervous system drugs /certified fixed orthodontic courses by Indian d...Central nervous system drugs /certified fixed orthodontic courses by Indian d...
Central nervous system drugs /certified fixed orthodontic courses by Indian d...Indian dental academy
 
Eye and ear presentation
Eye and ear presentationEye and ear presentation
Eye and ear presentationElvalina
 
Ppt chapter 06
Ppt chapter 06Ppt chapter 06
Ppt chapter 06stanbridge
 
Drug metabolism ppt
Drug metabolism pptDrug metabolism ppt
Drug metabolism pptSameera Sam
 
Host microbe interaction in periodontal disease
Host microbe interaction in periodontal diseaseHost microbe interaction in periodontal disease
Host microbe interaction in periodontal diseaseDr Saif khan
 
Ppt chapter 38
Ppt chapter 38Ppt chapter 38
Ppt chapter 38stanbridge
 

Viewers also liked (20)

Ppt chapter 07-1
Ppt chapter 07-1Ppt chapter 07-1
Ppt chapter 07-1
 
Ppt15
Ppt15Ppt15
Ppt15
 
INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil
INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil
INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil
 
Cns drugs outline
Cns drugs  outlineCns drugs  outline
Cns drugs outline
 
Greece
GreeceGreece
Greece
 
cases and treatment of peptic ulcers
cases and treatment of peptic ulcerscases and treatment of peptic ulcers
cases and treatment of peptic ulcers
 
Ppt chapter 52-1
Ppt chapter 52-1Ppt chapter 52-1
Ppt chapter 52-1
 
Anti inflammatory drugs
Anti inflammatory drugsAnti inflammatory drugs
Anti inflammatory drugs
 
02.06.12(a): Drugs and the Liver
02.06.12(a): Drugs and the Liver02.06.12(a): Drugs and the Liver
02.06.12(a): Drugs and the Liver
 
Some Spotlights about Pain management
Some Spotlights about Pain managementSome Spotlights about Pain management
Some Spotlights about Pain management
 
Central nervous system drugs /certified fixed orthodontic courses by Indian d...
Central nervous system drugs /certified fixed orthodontic courses by Indian d...Central nervous system drugs /certified fixed orthodontic courses by Indian d...
Central nervous system drugs /certified fixed orthodontic courses by Indian d...
 
Eye and ear presentation
Eye and ear presentationEye and ear presentation
Eye and ear presentation
 
Ppt chapter 06
Ppt chapter 06Ppt chapter 06
Ppt chapter 06
 
Clinical Nsaids Usage
Clinical Nsaids UsageClinical Nsaids Usage
Clinical Nsaids Usage
 
Drug metabolism ppt
Drug metabolism pptDrug metabolism ppt
Drug metabolism ppt
 
Host microbe interaction in periodontal disease
Host microbe interaction in periodontal diseaseHost microbe interaction in periodontal disease
Host microbe interaction in periodontal disease
 
Acetaminophen poisoning
Acetaminophen poisoningAcetaminophen poisoning
Acetaminophen poisoning
 
Chapter 7 powerpoint
Chapter 7 powerpointChapter 7 powerpoint
Chapter 7 powerpoint
 
Ppt chapter 38
Ppt chapter 38Ppt chapter 38
Ppt chapter 38
 
Immunology
ImmunologyImmunology
Immunology
 

Similar to Ppt chapter 24

Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20stanbridge
 
Ppt chapter 49
Ppt chapter 49Ppt chapter 49
Ppt chapter 49stanbridge
 
Ppt chapter 16-1
Ppt chapter 16-1Ppt chapter 16-1
Ppt chapter 16-1stanbridge
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40stanbridge
 
Ppt chapter 53-1
Ppt chapter 53-1Ppt chapter 53-1
Ppt chapter 53-1stanbridge
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36stanbridge
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32stanbridge
 
Ppt chapter 21
Ppt chapter 21Ppt chapter 21
Ppt chapter 21stanbridge
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16stanbridge
 
Ppt chapter 44
Ppt chapter 44Ppt chapter 44
Ppt chapter 44stanbridge
 
Ppt chapter 33
Ppt chapter 33Ppt chapter 33
Ppt chapter 33stanbridge
 
Ppt chapter 26-1
Ppt chapter 26-1Ppt chapter 26-1
Ppt chapter 26-1stanbridge
 
Ppt chapter 35
Ppt chapter 35Ppt chapter 35
Ppt chapter 35stanbridge
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36stanbridge
 
Ppt chapter 32-1
Ppt chapter 32-1Ppt chapter 32-1
Ppt chapter 32-1stanbridge
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48stanbridge
 
Ppt chapter 36-1
Ppt chapter 36-1Ppt chapter 36-1
Ppt chapter 36-1stanbridge
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48stanbridge
 
Ppt chapter 43
Ppt chapter 43Ppt chapter 43
Ppt chapter 43stanbridge
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37stanbridge
 

Similar to Ppt chapter 24 (20)

Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20
 
Ppt chapter 49
Ppt chapter 49Ppt chapter 49
Ppt chapter 49
 
Ppt chapter 16-1
Ppt chapter 16-1Ppt chapter 16-1
Ppt chapter 16-1
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40
 
Ppt chapter 53-1
Ppt chapter 53-1Ppt chapter 53-1
Ppt chapter 53-1
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32
 
Ppt chapter 21
Ppt chapter 21Ppt chapter 21
Ppt chapter 21
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
 
Ppt chapter 44
Ppt chapter 44Ppt chapter 44
Ppt chapter 44
 
Ppt chapter 33
Ppt chapter 33Ppt chapter 33
Ppt chapter 33
 
Ppt chapter 26-1
Ppt chapter 26-1Ppt chapter 26-1
Ppt chapter 26-1
 
Ppt chapter 35
Ppt chapter 35Ppt chapter 35
Ppt chapter 35
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36
 
Ppt chapter 32-1
Ppt chapter 32-1Ppt chapter 32-1
Ppt chapter 32-1
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 
Ppt chapter 36-1
Ppt chapter 36-1Ppt chapter 36-1
Ppt chapter 36-1
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 
Ppt chapter 43
Ppt chapter 43Ppt chapter 43
Ppt chapter 43
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37
 

More from stanbridge

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecturestanbridge
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2stanbridge
 
Creating a poster
Creating a posterCreating a poster
Creating a posterstanbridge
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Disseminationstanbridge
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5stanbridge
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4stanbridge
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors stanbridge
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learnerstanbridge
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policystanbridge
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentstanbridge
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005stanbridge
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007stanbridge
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006stanbridge
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004stanbridge
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009stanbridge
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008stanbridge
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21stanbridge
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22stanbridge
 

More from stanbridge (20)

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecture
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2
 
Creating a poster
Creating a posterCreating a poster
Creating a poster
 
Sample poster
Sample posterSample poster
Sample poster
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learner
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policy
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
 
Ot5101 week1
Ot5101 week1Ot5101 week1
Ot5101 week1
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22
 

Ppt chapter 24

  • 1. Chapter 24 Drugs Treating Mild to Moderate Pain, Fever, Inflammation, and Migraine Headache Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 2. Fever • Temperature regulation is a function of the hypothalamus. • Normally, a homeostatic balance exists between body heat generated and body heat lost. • Fever is the result of fever-inducing substances called pyrogens. • Fever causes activation of monocytes/macrophages, which in turn secrete cytokines. • Cytokines increase the synthesis and secretion of prostaglandin in the hypothalamus. • This causes the hypothalamus to reset the body temperature. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 3. Inflammation • Numerous types of stimuli cause the inflammatory response. • The classic signs of local inflammation are swelling, heat, redness, pain, and loss of function. • Acute inflammation is divided into vascular and cellular responses. • The vascular response occurs almost immediately after the injury. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 4. Inflammation (cont.) • The cellular response is divided into four phases: – Margination of white blood cells (WBCs) to the periphery of the blood vessels – Emigration of WBCs—the WBCs migrate into the tissue spaces. – Chemotaxis—cellular debris become more “attractive” to the WBCs. – Phagocytosis—neutrophils and monocytes engulf cellular debris. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 5. Prostaglandin Synthesis • Prostaglandins modulate some components of inflammation, body temperature, pain transmission, platelet aggregation, and many other body actions. • They are derived from arachidonic acid, which is liberated from the cell membrane in response to physical, chemical, hormonal, bacterial, or other stimuli. • They are converted from arachidonic acid to prostaglandins by the enzyme cyclooxygenase (COX). • There are two forms of the COX enzyme: COX-1 and COX- 2. • COX-1 synthesizes prostaglandins that are involved in the regulation of normal cell activity. • COX-2 appears to produce prostaglandins mainly at the sites of inflammation. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 6. Prostaglandin Synthesis (cont.) Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 7. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Pain • The physiologic mechanisms involved in the pain response are complex. • The sensation of peripheral pain begins in afferent neurons called nociceptors. • These receptors are activated by chemical mediators, such as prostaglandins, histamine, bradykinin, and serotonin.
  • 8. Platelet Aggregation • Simply speaking, platelet aggregation is the clumping together of platelets in the blood. • Platelet aggregation can be a beneficial process. • Platelet aggregation can also be harmful. It is the first step in a sequence of events that leads to the formation of a thrombus. • The risk of platelet aggregation is increased in patients who smoke and have hypercholesterolemia. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 9. Migraine Headache • The two major types of migraine headache: – Migraine with aura – Migraine without aura • It is postulated that migraine begins when intracranial blood vessels dilate. • This dilation stimulates the trigeminovascular system, resulting in abnormally excitable neurons that send pain impulses to the brain’s pain receptors. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 10. Drugs to Treat Inflammation and Fever • Salicylates, NSAIDs, and para-aminophenol derivative drugs are used to treat inflammation and fever in a variety of conditions. • Salicylates are used in managing conditions ranging from a simple headache to acute myocardial infarction (MI). • NSAIDs are used primarily as anti-inflammatory drugs but are also used extensively as analgesics. • Prototype drug: acetylsalicylic acid (aspirin) Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 11. Aspirin: Core Drug Knowledge • Pharmacotherapeutics – Treat mild-to-moderate pain, prevent platelet aggregation • Pharmacokinetics – Absorbed in the stomach and small intestines; highly protein bound • Pharmacodynamics – Fever: inhibited PGE2 synthesis in the hypothalamus – Inflammation: peripheral inhibition of prostaglandin – Antiplatelet: irreversible inhibition of thromboxane Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins A2
  • 12. Aspirin: Core Drug Knowledge (cont.) • Contraindications and precautions – Hypersensitivity, peptic ulcer disease, or bleeding disorders, and children with illness • Adverse effects – Renal failure, abnormal bleeding, GI upset, drowsiness, and confusion • Drug interactions – Other drugs that are highly protein bound Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 13. Aspirin: Core Patient Variables • Health status – Assess for contraindications to therapy. • Life span and gender – Contraindicated in the last trimester of pregnancy • Lifestyle, diet, and habits – Assess use of OTC medications. • Environment – Assess understanding of drug therapy. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 14. Aspirin: Nursing Diagnoses and Outcomes • Acute or chronic pain related to ineffectiveness of aspirin – Desired outcome: The patient will contact the prescriber if pain persists. • Risk for Injury: GI bleeding, hepatic or renal toxicity related to aspirin therapy – Desired outcome: The patient will avoid injury by contacting the prescriber if any signs of toxicity occur. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 15. Aspirin: Nursing Diagnoses and Outcomes (cont.) • Disturbed Sensory Perception (visual and auditory) related to blurred vision or tinnitus – Desired outcome: The patient will contact the prescriber if blurred vision or tinnitus occurs. • Ineffective Protection related to blood dyscrasias or rash – Desired outcome: The patient will contact the prescriber if any signs of blood dyscrasias or rash occur. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 16. Aspirin: Nursing Diagnoses and Outcomes (cont.) • Deficient Fluid Volume related to nausea and vomiting – Desired outcome: The patient will avoid dehydration by contacting the prescriber if persistent nausea or vomiting occurs. • Risk for Injury related to self-medication – Desired outcome: The patient will avoid injury by taking aspirin as prescribed. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 17. Aspirin: Planning and Interventions • Maximizing therapeutic effects – Give with milk or food to decrease GI upset. – When giving aspirin for its cardiovascular properties, use uncoated aspirin. • Minimizing adverse effects – Do not administer aspirin to a patient with a medical condition that contraindicates its use. – It is important to monitor closely patients with pre-existing medical conditions or those on drug therapy that may interact with aspirin. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 18. Aspirin: Teaching, Assessment, and Evaluations • Patient and family education – Teach proper administration of medication. – Discuss side effects of therapy. • Ongoing assessment and evaluation – Monitor the patient who is taking aspirin for signs and symptoms of GI distress or bleeding, anemia, hepatotoxicity, and renal failure. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 19. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Question • Why is aspirin contraindicated in children with varicella? – A. Can cause bleeding from skin lesions – B. Will decrease effectiveness of antibiotic therapy – C. Can cause increased fever – D. Can cause Reye syndrome
  • 20. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Answer • D. Can cause Reye syndrome • Rationale: Aspirin is contraindicated in children with varicella or flu-like illness because it is associated with the occurrence of Reye syndrome.
  • 21. Nonsteroidal Anti-Inflammatory Drugs • The NSAIDs are grouped by chemical classes. • NSAIDs all inhibit COX and prostaglandin synthesis. • The therapeutic efficacy of an NSAID in a particular patient is based on clinical response and usually cannot be predicted before its use. • All NSAIDs carry a Black Box warning stating that they increase the risk of MI and stroke. • Prototype drug: ibuprofen Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 22. Ibuprofen: Core Drug Knowledge • Pharmacotherapeutics – Arthritis, mild-to-moderate pain, primary dysmenorrhea, migraine headache, and fever • Pharmacokinetics – Absorbed from the GI system. Peak: 1 to 2 hours. Highly protein bound and is metabolized in the liver • Pharmacodynamics – Inhibited synthesis or release of prostaglandins Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 23. Ibuprofen: Core Drug Knowledge (cont.) • Contraindications and precautions – GI disease • Adverse effects – GI upset and bleeding, hepatotoxicity, and acute renal failure. Increases risk of CVA or MI with prolonged use. • Drug interactions – Similar to those of salicylates Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 24. Ibuprofen: Core Patient Variables • Health status – Assess for contraindications to therapy. • Life span and gender – Assess age before administration of drug. • Lifestyle, diet, and habits – Assess other OTC use. • Environment – Assess environment where drug will be given. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 25. Ibuprofen: Nursing Diagnoses and Outcomes • Acute or Chronic Pain related to ineffectiveness of ibuprofen – Desired outcome: The patient will contact the prescriber if pain persists. • Increased Risk for Injury related to incorrect self-administration or to drug-induced GI bleeding or hepatic and renal toxicity – Desired outcome: The patient will remain free of injury by taking the drug only as directed. In addition, the patient will be able to explain the importance of contacting the health care provider immediately if any adverse effects occur. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 26. Ibuprofen: Nursing Diagnoses and Outcomes (cont.) • Increased Risk for Deficient Fluid Volume related to nausea and vomiting – Desired outcome: The patient will contact the prescriber immediately if intractable nausea or vomiting occurs. • Disturbed Sensory Perception (visual) related to blurred vision – Desired outcome: The patient will discontinue ibuprofen immediately and contact the health care provider if vision is affected. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 27. Ibuprofen: Nursing Diagnoses and Outcomes (cont.) • Ineffective Protection related to blood dyscrasias – Desired outcome: The patient will contact the prescriber immediately if any signs and symptoms of blood dyscrasias occur. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 28. Ibuprofen: Planning and Interventions • Maximizing therapeutic effects – Give ibuprofen with milk or food to decrease gastric Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins distress. • Minimizing adverse effects – Closely monitor patients with pre-existing medical conditions or drug therapy that may interact with ibuprofen.
  • 29. Ibuprofen: Teaching, Assessment, and Evaluations • Patient and family education – Teach patient about cardiovascular risk from medication. – Teach about side effects of drug therapy. • Ongoing assessment and evaluation – Monitor for side effects of therapy. – Therapy is considered effective if the patient is free of fever, pain, or inflammation and is free from adverse effects. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 30. Question • Why were all NSAIDs given a Black Box warning by the FDA? – A. Risk of MI and CVA is increased with use of Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins NSAIDs. – B. Risk of GI bleeding is increased with use of NSAIDs. – C. NSAIDs can cause kidney failure. – D. NSAIDs can cause hepatic failure.
  • 31. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Answer • A. Risk of MI and CVA is increased with use of NSAIDs. • Rationale: All NSAIDs have a risk of causing MI or CVA; the risk increases with prolonged use of the medication.
  • 32. Para-Aminophenol Derivatives • Para-aminophenol derivative is an analgesic and antipyretic available in the United States. • Prototype drug: acetaminophen (Tylenol) Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 33. Acetaminophen: Core Drug Knowledge • Pharmacotherapeutics – Used to treat fever or mild pain • Pharmacokinetics – Administered orally. Absorbed: GI tract. Peak: 60 minutes. T1/2: 1 to 3.5 hours • Pharmacodynamics – Primarily centrally acting; inhibits prostaglandin synthesis in the CNS Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 34. Acetaminophen: Core Drug Knowledge (cont.) • Contraindications and precautions – Hepatic disease, viral hepatitis, or alcoholism • Adverse effects – Generally well tolerated; overdose of medication can Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins be fatal • Drug interactions – Activated charcoal, antacids, ethanol, hydantoins, warfarin, and sulfinpyrazone
  • 35. Acetaminophen: Core Patient Variables • Health status – Assess pain level and current medical conditions. • Life span and gender – Pregnancy category B • Lifestyle, diet, and habits – Ask about other OTC medication use. • Environment – Determine patient’s understanding of drug use. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 36. Acetaminophen: Nursing Diagnoses and Outcomes • Acute or Chronic Pain related to ineffectiveness of acetaminophen – Desired outcome: The patient will contact the health care provider if pain persists. • Risk for Injury related to drug-induced hepatic and renal toxicity or to improper self-medication – Desired outcome: The patient will take drug as directed and contact the health care provider if any signs of toxicity occur. • Ineffective Protection related to potential blood dyscrasias – Desired outcome: The patient will contact the health care provider if any signs of blood dyscrasias occur. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 37. Acetaminophen: Planning and Interventions • Maximizing therapeutic effects – Acetaminophen can be administered without regard Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins to meals. • Minimizing adverse effects – Assess patients for medical conditions that contradict the use of acetaminophen. – Coordinate periodic CBC, platelet count, and liver and renal function tests for patients on long-term therapy.
  • 38. Acetaminophen: Teaching, Assessment, and Evaluations • Patient and family education – Teach patient to take medication as prescribed. – Teach side effects of medication. – Instruct that many OTC medications contain Tylenol. • Ongoing assessment and evaluation – Monitor patient for side effects from the medication. – Therapy is considered effective if patient is free of fever and pain. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 39. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Question • Which of the following patients is Tylenol contraindicated in? – A. 25 year old with headache – B. 45 year old with GI bleeding – C. 52 year old with hepatitis C – D. 62 year old with osteoarthritis
  • 40. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Answer • C. 52 year old with hepatitis C • Rationale: Tylenol is contraindicated in patients with impaired liver/hepatic function.
  • 41. Serotonin-Selective Drugs • Serotonin-selective drugs are used to relieve pain and inflammation related to migraine headache. • They are not useful for other types of headache or inflammation that occur elsewhere in the body. • These drugs are also known as “triptans” because the generic name of these drugs ends as such. • The triptans are considered first-line drugs for the treatment of acute migraine headache. • Prototype drug: sumatriptan (Imitrex) Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 42. Sumatriptan: Core Drug Knowledge • Pharmacotherapeutics – Acute migraine headache and cluster headache • Pharmacokinetics – Administered orally, intranasally, or subcutaneously. Metabolized in the liver and excreted by the kidneys. • Pharmacodynamics – Selective for 5-HT1B/1D receptors located on cranial blood vessels and sensory nerves of the trigeminovascular system. – Stimulation of these receptors results in vasoconstriction. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 43. Sumatriptan: Core Drug Knowledge (cont.) • Contraindications and precautions – Coronary artery disease and ischemic cardiac Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins diseases • Adverse effects – Coronary artery vasospasm, cardiac dysrhythmias angina, myocardial ischemia, and dizziness • Drug interactions – Selective serotonin reuptake inhibitors and monoamine oxidase inhibitors
  • 44. Sumatriptan: Core Patient Variables • Health status – Assess the characteristics of the headache. • Life span and gender – Pregnancy category C • Lifestyle, diet, and habits – Identify trigger factors for headaches. • Environment – Given in the outpatient setting Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 45. Sumatriptan: Nursing Diagnoses and Outcomes • Risk for Tissue Perfusion, Impaired, related to cardiovascular or cerebrovascular events – Desired Outcome: The patient will recognize the signs and symptoms of cardiovascular or cerebrovascular events and seek medical assistance immediately. • Risk for Injury related to weakness, dizziness or syncope, or lightheadedness – Desired Outcome: The patient will remain free of injury while taking sumatriptan. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 46. Sumatriptan: Planning and Interventions • Maximizing therapeutic effects – Confirm diagnosis of type of headache the patient is Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins having. – Administer drug as soon as headache begins. • Minimizing adverse effects – Assess the patient for a history of cardiovascular or cerebrovascular disorder. – After administering sumatriptan, monitor for signs and symptoms of vasospasm and allergy.
  • 47. Sumatriptan: Teaching, Assessment, and Evaluations • Patient and family education – Teach how to take medication properly. – Teach side effects of medication. – Teach patient to identify triggers. • Ongoing assessment and evaluation – Evaluate patients taking sumatriptan for the cessation of headache and for signs and symptoms of vasospastic events. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 48. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Question • Which of the following is the most serious adverse effect of sumatriptan? – A. Cardiac event – B. Respiratory event – C. Urinary event – D. GI event
  • 49. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Answer • A. Cardiac event • Rationale: The most serious adverse effect is cardiac events, however, they rarely occur.